Faraday Pharmaceuticals To Participate In Upcoming Investor Events

2025-09-11 12:01:31

(MENAFN- GlobeNewsWire - Nasdaq) Topline data from pivotal Phase 3 Iocyte AMI-3 trial expected in Q4 2025

SEATTLE, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on preventing heart failure by reducing myocardial damage in acute ST-elevation myocardial infarction (STEMI) through the reduction of ischemia-reperfusion injury, today announced that management will be participating in the following upcoming virtual investor events:

Oppenheimer's Private Life Sciences Company Showcase

Date:	Thursday, September 25, 2025
Format:	Company presentation and one-on-one meetings
Presentation Time:	1:45 PM ET

Cantor Private Biotech Company Series

Date:	Friday, October 3, 2025
Format:	Fireside Chat
Presentation Time:	12:00 PM ET

5 ^th Annual Needham Private Biotech and MedTech Company Forum

Date:	October 14 – 15, 2025
Format:	One-on-one meetings

Please contact your institutional representative to request a one-on-one meeting with management. To attend the Cantor fireside chat webinar, please contact your research representative for a registration link.

About Faraday Pharmaceuticals, Inc.
Faraday Pharmaceuticals^® is a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage in acute STEMI. The company was founded by Dr. Mark Roth of the Fred Hutch Cancer Center and is backed by an investor group led by ARCH Venture Partners and Polaris Partners. The company is headquartered in Seattle. For more information, visit or follow the company on LinkedIn .

Contact:
Brian Blackman
Chief Financial Officer
...

PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
...

MENAFN11092025004107003653ID1110049645

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.